AAV tracing experiment design comes down to nine decisions, and they have to be made in order: direction, serotype, promoter, cargo, titre, volume, survival time, controls, and group size. There is no single AAV tracing protocol that fits every pathway — what transfers between studies is the sequence of those decisions and the control groups that protect the conclusion. Stages 1 to 4 decide what you order. Stages 5 to 7 decide what you do at the bench. Stages 8 and 9 decide whether the result survives review.
If you have not yet decided whether AAV tracing is the right method at all, start with the companion guide, AAV Tracing: How Anterograde and Retrograde Labelling Work. It covers what each capsid does and what the method can and cannot show. This guide assumes that decision is made and takes you from question to order sheet.
The nine stages of AAV tracing experiment design
- State the question as a direction — decides the capsid
- Choose the serotype — then confirm it in your own model
- Choose the promoter — decides which cells express the label
- Choose the cargo — reporter only, or reporter plus function
- Set titre and volume — these two numbers shape your figure
- Set the survival time — too short is the most common error
- Build the control groups — the part reviewers ask about
- Plan the readout — decide before perfusion, not after
- Set group size and blinding — write the exclusion rule in advance
Stages 1–4: deciding what goes in the tube
Stage 1 — State the question as a direction
Write your question as one sentence, then check which of three shapes it takes. This single step removes most later confusion, because direction is the property the capsid controls, not the cargo.
- “Where does region A send its axons?” → anterograde labelling. Inject in A. Look for terminals downstream.
- “Which regions send axons into region A?” → retrograde labelling. Inject in A. Look for cell bodies upstream.
- “Which neurons in region B receive input from region A?” → anterograde transsynaptic tagging. Inject a recombinase in A, supply a recombinase-dependent reporter in B (Zingg et al., Neuron 2017; step-by-step in Zingg et al., Curr Protoc 2022).
Stage 2 — Choose the serotype, then confirm it in your own model
The serotype follows from Stage 1. Below are the usual starting points in rodent work. Treat them as a first guess, not a specification, because tropism changes with species, brain region, promoter, and titre.
| Your direction | Usual starting serotype | Browse |
|---|---|---|
| Anterograde, wide local coverage | AAV5, AAV8, AAV9 | AAV5 · AAV8 · AAV9 |
| Anterograde, tightly restricted site | AAV2 — spreads least from the needle | AAV2 |
| Anterograde transsynaptic tagging | AAV1 or AAV9, carrying Cre or Flp | AAV1 |
| Retrograde | rAAV2-retro (Tervo et al. 2016) | AAV Vector Research |
Some vectors in the Adeno-Associated Viruses (AAVs) catalog are supplied pack-ready, which means the plasmid is held in stock and you select the serotype when you order. On those products rAAV2-retro appears as one of the serotype options, alongside AAV2/1, AAV2/5, AAV2/9, and the PHP capsids.
Reporter vectors commonly used for that pilot: scAAV-GFP (AAV9, self-complementary) under a CMV promoter for broad expression; scAAV-Synapsin-GFP (AAV9) for the same capsid with a neuron-restricted promoter; and scAAV-GFP (AAV4) or scAAV-Synapsin-GFP (AAV-DJ) when you want to compare tropism across capsids.
Stage 3 — Choose the promoter
The serotype decides which cells the vector enters. The promoter decides which of those cells switch the gene on. These are two separate filters, and confusing them is a frequent source of surprise.
| Promoter | Expresses in | Choose it when |
|---|---|---|
| CAG, CMV, EF1α | Broad, most cell types | You want maximum brightness and do not need selectivity |
| hSyn (synapsin) | Neurons | You need to exclude glia from the label |
| CaMKIIα | Favours excitatory forebrain neurons | You are studying excitatory projections |
| GFAP | Favours astrocytes | Your question is glial, not neuronal |
Stage 4 — Choose the cargo
Decide now, not later, whether this experiment is anatomy only. If you will eventually want to record from or manipulate the labelled neurons, choosing the cargo now saves a whole round of surgeries.
| Level | Cargo | Example construct |
|---|---|---|
| Anatomy only | A fluorescent protein such as GFP or mCherry — simplest and cheapest | scAAV-GFP (AAV9) |
| Genetic access | A recombinase such as Cre, paired with a Cre-dependent construct — required for transsynaptic tagging and projection-defined manipulation | AAV-CMV-EGFP-P2A-Cre |
| Anatomy plus function | A calcium indicator, an opsin, or a chemogenetic receptor, so the same neurons can be imaged or controlled | AAV-hSyn-GCaMP6s-P2A-Cre · AAV-hSyn-ChrimsonR-GFP |
Stages 5–6: AAV titre, injection volume, and survival time
Stage 5 — Set titre and volume
Titre and volume together set the size of the effective injection site. This is not a detail. A site that is larger than you think will make a projection look broader than it is, and can label neurons you did not intend to reach.
- Start from the three papers you tabulated for your own pathway. Copy their values.
- For orientation only: rodent stereotaxic tracing work commonly uses titres in the range of 1012 to 1013 genome copies per mL, and volumes from under one hundred nanolitres up to a few hundred nanolitres per site. Small structures need the low end.
- Inject slowly, then wait several minutes before withdrawing the needle. This reduces backflow along the needle track.
- Keep titre and volume identical across every group you intend to compare.
Stage 6 — Set the survival time
The vector genome must be converted to double-stranded DNA before transcription begins, so expression is never immediate. Cell bodies fill first. Distal axon terminals fill last.
- Signal usually becomes detectable after one to two weeks.
- Three to four weeks is a common survival time so that long-range terminals are fully labelled. Published AAV1 transsynaptic work frequently uses four weeks (Zingg et al., Neuron 2017).
- Self-complementary vectors skip the conversion step and express sooner.
- If you are unsure, perfuse a small pilot group at two time points and compare.
Stage 7 — AAV tracing controls that survive peer review
AAV tracing controls are where most results fail review, not at the bench. The controls below are not optional extras. Each one closes a specific alternative explanation for your labelling pattern. Choose the rows that match your design.
| Control | What it rules out | Include it when |
|---|---|---|
| Off-target injection site | That your labelling comes from vector spread beyond the intended region. Inject the same vector into a neighbouring region known not to project to your target. | Always, for any projection claim |
| Reporter-only group | That the recombinase-dependent construct expresses without the recombinase. Inject only the Cre-dependent vector, with no Cre. | Any Cre-dependent or Flp-dependent design |
| Recombinase-only group | That the recombinase itself caused your effect. AAV-mediated Cre expression at commonly used titres has been reported to cause neuronal loss and behavioural change in the injected region, independently of any floxed target (Rezai Amin et al., J Neurochem 2019). | Any design using Cre, especially with a behavioural readout |
| Empty or scrambled cargo vector | That the vector, promoter, or surgery produced the effect rather than your payload. | Any design where the cargo is meant to do something |
| Direction control | That labelling travelled in the unintended direction. For transsynaptic designs, confirm the anatomical plausibility of every labelled region; a weaker retrograde component is reported for AAV1 (Zingg et al., J Neurosci 2020). | Transsynaptic and retrograde designs |
| Matched titre and volume | That a difference between groups came from dose rather than biology. | Any comparison between groups |
A control vector should match the experimental vector in serotype, promoter, titre, and volume — only the cargo should differ. For the scrambled-cargo arm, scAAV-EF1a-ctrl-miR-eGFP carries a scrambled miRNA with a visible reporter; for the no-recombinase arm, a plain reporter such as scAAV-GFP (AAV9) is the usual choice.
Stages 8–9: readout, group size, and exclusion rules
Stage 8 — Plan the readout
How you will image the tissue affects how you should fix and section it. Deciding late usually means re-running animals. Two questions settle it:
- Native fluorescence or immunostaining? Native signal is often enough for cell bodies. Staining against GFP or mCherry recovers thin distal axons, weakly expressing cells, and signal in thick tissue. Anti-GFP and anti-RFP reagents sit in the antibodies catalog.
- Sections or whole brain? Serial sections suit quantification by region. Cleared whole brains suit describing a complete projection pattern, but need a different fixation and imaging pipeline.
Stage 9 — Set group size and blinding
- Expect to lose animals. Injection sites miss. Plan a surplus so that a missed site does not leave a group underpowered.
- Write the exclusion rule first. “Excluded if the injection site extends beyond the target border” is defensible. Deciding after seeing the data is not.
- Blind the scoring. Whoever counts labelled cells should not know which group each section came from.
- Randomise across surgery days. Do not run all controls in one session and all experimental animals in another. Order effects are real.
One-page AAV tracing experiment design planning sheet
This is the whole AAV tracing experimental design summarised on one page. Fill it in before you order anything. If a row is blank, that is the next decision to make.
| Item | Your value | Decided at |
|---|---|---|
| Question, written as a direction | Stage 1 | |
| Serotype | Stage 2 | |
| Pilot done, tropism confirmed? | Stage 2 | |
| Promoter | Stage 3 | |
| Cargo | Stage 4 | |
| Total cassette length under the packaging limit? | Stage 4 | |
| Titre as injected | Stage 5 | |
| Volume per site, and injection rate | Stage 5 | |
| Coordinates | Stage 5 | |
| Survival time | Stage 6 | |
| Control groups, listed | Stage 7 | |
| Readout: native or stained | Stage 8 | |
| Group size, plus surplus | Stage 9 | |
| Exclusion rule, written | Stage 9 |
Five AAV tracing design mistakes that are hard to fix later
- Skipping the pilot. Two animals and one reporter vector cost far less than a full cohort injected with a capsid that does not transduce your region.
- Perfusing too early. Distal terminals fill last. A two-week survival time can hide a real long-range projection completely.
- Changing titre mid-study. The animals injected before the change and after it are no longer comparable, and no analysis can repair that.
- No recombinase-only group. If Cre alone can change your readout, a result attributed to your floxed target may not belong to it (Rezai Amin et al. 2019).
- Assuming a capsid transfers across strains or species. Enhanced brain entry of the PHP.B family is strain-dependent and receptor-dependent (Hordeaux et al. 2019). Confirm in your own model before you build a study on it.
AAV tracing experiment design FAQ
Is there a standard AAV tracing protocol?
No single protocol fits every pathway. Serotype, titre, volume, and survival time all change with the region and the species, so a value copied from an unrelated study is not reliable. What does transfer is the order of decisions in this workflow, and the control groups in Stage 7. Take the numbers from published work on your own pathway.
What titre should I use for AAV tracing?
Take the value from published work on your own pathway rather than from a general recommendation. Rodent tracing studies commonly use titres of 1012 to 1013 genome copies per mL. Whatever you choose, keep it identical across all compared groups, and report it.
How do I choose a survival time for my own pathway?
Work from the distance the axons must travel. Short local projections fill sooner than long-range ones, so a survival time copied from a local circuit will under-report a distant target. Take the value from published work on your pathway, and if no close match exists, perfuse a small pilot group at two time points and compare terminal filling before committing the cohort.
Which AAV tracing controls do I actually need?
At minimum, an off-target injection site control for any projection claim. Add a reporter-only group for any recombinase-dependent design, and a recombinase-only group whenever Cre is used with a functional or behavioural readout (Rezai Amin et al. 2019).
Can one injection answer both directions?
In practice, no. Direction is a property of the capsid, and mixing directions in one animal makes each labelled cell ambiguous. Use separate cohorts, or separate injection sites with distinguishable fluorescent proteins (Tervo et al. 2016).
Do I need a self-complementary vector?
Only if you need faster expression or a shorter survival time. Self-complementary vectors skip the second-strand conversion step, but carry roughly half the cargo of a standard single-stranded vector.
How many animals per group?
This depends on your readout and effect size, so no single number applies. What matters procedurally is planning a surplus for missed injection sites, and writing the exclusion rule before looking at the tissue.
Order the pilot before the cohort
If the planning sheet is complete except for the serotype row, the pilot in Stage 2 is the fastest way to fill it. Trial-pack reporter vectors exist for exactly this purpose. Browse the full AAV Vector Research range, or talk to a BioHippo technical specialist about your pathway, capsid options, and control groups before you order.
References
- Tervo DGR, Hwang BY, Viswanathan S, et al. A designer AAV variant permits efficient retrograde access to projection neurons. Neuron. 2016;92(2):372–382. PMID 27720486 · doi:10.1016/j.neuron.2016.09.021
- Zingg B, Chou XL, Zhang ZG, et al. AAV-mediated anterograde transsynaptic tagging: mapping corticocollicular input-defined neural pathways for defense behaviors. Neuron. 2017;93(1):33–47. PMID 27989459 · doi:10.1016/j.neuron.2016.11.045
- Zingg B, Peng B, Huang J, Tao HW, Zhang LI. Synaptic specificity and application of anterograde trans-synaptic AAV for probing neural circuitry. J Neurosci. 2020;40(16):3250–3267. PMID 32198185 · doi:10.1523/JNEUROSCI.2158-19.2020
- Hordeaux J, Yuan Y, Clark PM, et al. The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier. Mol Ther. 2019;27(5):912–921. PMID 30819613 · doi:10.1016/j.ymthe.2019.02.013
- Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The neurotropic properties of AAV-PHP.B are limited to C57BL/6J mice. Mol Ther. 2018;26(3):664–668. PMID 29428298 · doi:10.1016/j.ymthe.2018.01.018
- Zingg B, Dong HW, Tao HW, Zhang LI. Application of AAV1 for anterograde transsynaptic circuit mapping and input-dependent neuronal cataloging. Curr Protoc. 2022;2(1):e339. PMID 35044725 · doi:10.1002/cpz1.339
- Rezai Amin S, Gruszczynski C, Guiard BP, et al. Viral vector-mediated Cre recombinase expression in substantia nigra induces lesions of the nigrostriatal pathway associated with perturbations of dopamine-related behaviors and hallmarks of programmed cell death. J Neurochem. 2019;150(3):330–340. PMID 30748001 · doi:10.1111/jnc.14684
This guide describes published methodology and does not replace the original protocols or your institution's approved procedures. Titre, volume, survival time, and capsid performance must be validated in your own model, species, and pathway. All products are for research use only.
